By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

MediciNova, Inc. 

4350 La Jolla Village Drive, Suite 950

San Diego  California  92122  U.S.A.
Phone: 858-373-1500 Fax: 858-373-7000


SEARCH JOBS


Industry
Biotechnology






Company News
FDA Grants Fast Track Designation For MediciNova, Inc.'s MN-166 (Ibudilast) For The Treatment Of Amyotrophic Lateral Sclerosis 12/16/2015 7:52:26 AM
MediciNova, Inc. Announces Presentation Regarding Clinical Trial Of MN-166 (Ibudilast) In ALS At The 6th Annual California ALS Pac10 And Research Network Meeting At University of California, San Diego (UCSD), La Jolla, California 12/7/2015 10:48:52 AM
MediciNova, Inc. To Initiate Clinical Trial Evaluating MN-001 In NASH Patients With Hypertriglyceridemia 11/19/2015 11:04:29 AM
MediciNova, Inc. Receives Notice Of Allowance For New Patent Covering MN-221 (Bedoradrine) For The Treatment Of Irritable Bowel Syndrome In Japan 11/11/2015 9:55:43 AM
FDA Approves A New Clinical Protocol To Evaluate The Effects Of MN-166 (Ibudilast) On A Biomarker Of ALS; MediciNova, Inc. Plans To Initiate A Clinical Trial With Massachusetts General Hospital 11/10/2015 10:11:35 AM
MediciNova, Inc. Announces Interim Data From Clinical Trial Of Mn-166 (Ibudilast) In ALS To Be Presented At The 14th Annual NEALS (Northeast Amyotrophic Lateral Sclerosis) Meeting In Clearwater Beach, Florida 11/4/2015 10:37:20 AM
MediciNova, Inc. To Initiate Clinical Trial Of MN-001 (Tipelukast) In IPF 10/9/2015 7:13:57 AM
MediciNova, Inc. To Present At The Ladenburg Thalmann 2015 Healthcare Conference 9/24/2015 9:50:38 AM
FDA Grants Fast Track Designation For MediciNova, Inc.'s MN-001 (Tipelukast) For The Treatment Of Idiopathic Pulmonary Fibrosis 9/10/2015 7:22:15 AM
MediciNova, Inc. Announces First Advanced ALS Patient Using Non-Invasive Ventilation Support Enrolled In Phase II Clinical Trial Of MN-166 (Ibudilast) 9/3/2015 7:14:56 AM
12345678910...
//-->